NO326398B1 - Nytt glykolipid og medisin for autoimmunsykdom inneholdende det samme som aktiv ingrediens. - Google Patents

Nytt glykolipid og medisin for autoimmunsykdom inneholdende det samme som aktiv ingrediens. Download PDF

Info

Publication number: NO326398B1
Authority: NO; Norway
Prior art keywords: compound; galactosyl; synthesis; nmr; glycolipids
Prior art date: 2001-08-16

Application number

NO20040653A

Other languages

English (en)

Norwegian (no)

Other versions

NO20040653L (no

Inventor

Takashi Yamamura

Sachiko Miyake

Original Assignee

Japan Government

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-16

Filing date

2004-02-13

Publication date

2008-11-24

2004-02-13 Application filed by Japan Government filed Critical Japan Government

2004-05-07 Publication of NO20040653L publication Critical patent/NO20040653L/no

2008-11-24 Publication of NO326398B1 publication Critical patent/NO326398B1/no

Links

HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 title claims abstract description 18
229930186217 Glycolipid Natural products 0.000 title claims description 54
208000023275 Autoimmune disease Diseases 0.000 title claims description 34
239000003814 drug Substances 0.000 title claims description 17
239000004480 active ingredient Substances 0.000 title claims description 11
201000010099 disease Diseases 0.000 claims description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
229940079593 drug Drugs 0.000 claims description 12
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
230000001575 pathological effect Effects 0.000 claims description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
230000017307 interleukin-4 production Effects 0.000 claims description 7
125000003550 alpha-D-galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims description 4
WQZGKKKJIJFFOK-UHFFFAOYSA-N hexopyranose Chemical group OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 claims description 3
239000000411 inducer Substances 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 16
230000001506 immunosuppresive effect Effects 0.000 abstract description 3
208000030767 Autoimmune encephalitis Diseases 0.000 abstract 1
238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 abstract 1
230000002456 anti-arthritic effect Effects 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000002682 anti-psoriatic effect Effects 0.000 abstract 1
230000003356 anti-rheumatic effect Effects 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
239000003435 antirheumatic agent Substances 0.000 abstract 1
230000001553 hepatotropic effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
YGOYMNMFBVUFOH-UHFFFAOYSA-N nonane-1,1,4-triol Chemical compound CCCCCC(O)CCC(O)O YGOYMNMFBVUFOH-UHFFFAOYSA-N 0.000 abstract 1
239000012873 virucide Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 description 80
230000015572 biosynthetic process Effects 0.000 description 61
238000003786 synthesis reaction Methods 0.000 description 59
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 49
238000000034 method Methods 0.000 description 42
238000005160 1H NMR spectroscopy Methods 0.000 description 37
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 31
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
239000000203 mixture Substances 0.000 description 25
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 23
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
210000000581 natural killer T-cell Anatomy 0.000 description 20
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 18
229940125846 compound 25 Drugs 0.000 description 18
201000002491 encephalomyelitis Diseases 0.000 description 18
VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 description 14
108090000978 Interleukin-4 Proteins 0.000 description 14
241000699670 Mus sp. Species 0.000 description 14
230000001629 suppression Effects 0.000 description 14
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
239000000243 solution Substances 0.000 description 13
239000002904 solvent Substances 0.000 description 13
238000011282 treatment Methods 0.000 description 13
ZMLPBBXPGNHINZ-HBGSFDFLSA-N n-[(2s,3s,4r)-3,4-dihydroxy-1-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptan-2-yl]tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZMLPBBXPGNHINZ-HBGSFDFLSA-N 0.000 description 12
210000004989 spleen cell Anatomy 0.000 description 12
101150041968 CDC13 gene Proteins 0.000 description 11
102100037850 Interferon gamma Human genes 0.000 description 11
108010074328 Interferon-gamma Proteins 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 10
230000006870 function Effects 0.000 description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
108090000695 Cytokines Proteins 0.000 description 9
102000004127 Cytokines Human genes 0.000 description 9
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 9
208000009386 Experimental Arthritis Diseases 0.000 description 8
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
-1 α-D-mannosyl Chemical group 0.000 description 8
210000004027 cell Anatomy 0.000 description 7
238000010586 diagram Methods 0.000 description 7
239000000839 emulsion Substances 0.000 description 7
238000003818 flash chromatography Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
238000005259 measurement Methods 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
BWDGLGHSJMLTGW-IWVUWWQKSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptan-2-yl]octacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BWDGLGHSJMLTGW-IWVUWWQKSA-N 0.000 description 5
201000006417 multiple sclerosis Diseases 0.000 description 5
239000012044 organic layer Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 4
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 4
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
229940126657 Compound 17 Drugs 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
241001529936 Murinae Species 0.000 description 4
241000187479 Mycobacterium tuberculosis Species 0.000 description 4
HVTAVARNKZLHPK-CLTBVUQJSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptan-2-yl]hexacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O HVTAVARNKZLHPK-CLTBVUQJSA-N 0.000 description 4
LCMBEAHWQFBDMV-LQPUHCPASA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptan-2-yl]nonacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LCMBEAHWQFBDMV-LQPUHCPASA-N 0.000 description 4
BQFKYVWAIHQLCH-ZORUMLJWSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptan-2-yl]pentacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BQFKYVWAIHQLCH-ZORUMLJWSA-N 0.000 description 4
FALVVPJSMRYHFR-RQWCFLMLSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptan-2-yl]triacontanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O FALVVPJSMRYHFR-RQWCFLMLSA-N 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
229940126543 compound 14 Drugs 0.000 description 4
229940125810 compound 20 Drugs 0.000 description 4
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 4
239000001257 hydrogen Substances 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 4
230000008961 swelling Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
DGIYKLWEVUSOLJ-YAOOYPAMSA-N (2r,3r,4s,5r)-2,5-dihydroxy-3,4,6-tris(phenylmethoxy)hexanal Chemical compound C([C@@H](O)[C@H](OCC=1C=CC=CC=1)[C@H](OCC=1C=CC=CC=1)[C@@H](O)C=O)OCC1=CC=CC=C1 DGIYKLWEVUSOLJ-YAOOYPAMSA-N 0.000 description 3
102000006306 Antigen Receptors Human genes 0.000 description 3
108010083359 Antigen Receptors Proteins 0.000 description 3
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 3
108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 3
ZTOPTZFMOMSTSM-HVPSFVGRSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptan-2-yl]henicosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZTOPTZFMOMSTSM-HVPSFVGRSA-N 0.000 description 3
IYXAEBVCNZXIAH-BAHUXPPRSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctan-2-yl]nonadecanamide Chemical compound CCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O IYXAEBVCNZXIAH-BAHUXPPRSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000010171 animal model Methods 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
229940125833 compound 23 Drugs 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 3
210000002683 foot Anatomy 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
210000001503 joint Anatomy 0.000 description 3
210000003141 lower extremity Anatomy 0.000 description 3
DHORFKWFISWSSR-NOUVZJLJSA-N n-[(2s,3s,4r)-3,4-dihydroxy-1-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptan-2-yl]docosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DHORFKWFISWSSR-NOUVZJLJSA-N 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 3
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
ZILQQTIXFOPZFN-YFWOXBOYSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptan-2-yl]nonadecanamide Chemical compound CCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZILQQTIXFOPZFN-YFWOXBOYSA-N 0.000 description 2
USMNKRYVZSPXTD-UHTOCBDZSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonan-2-yl]nonacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O USMNKRYVZSPXTD-UHTOCBDZSA-N 0.000 description 2
JZPUQOBISFZYMO-QNAIHFNASA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctan-2-yl]docosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JZPUQOBISFZYMO-QNAIHFNASA-N 0.000 description 2
HPMXIGVZOCAMPQ-WVLAUNTOSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctan-2-yl]hexacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O HPMXIGVZOCAMPQ-WVLAUNTOSA-N 0.000 description 2
KRLDOAUJBJYGNI-LQPUHCPASA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctan-2-yl]octacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O KRLDOAUJBJYGNI-LQPUHCPASA-N 0.000 description 2
DNHNWSDNMTZZLB-CLTBVUQJSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctan-2-yl]pentacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DNHNWSDNMTZZLB-CLTBVUQJSA-N 0.000 description 2
VYEUHMFNZNPCQL-UHTOCBDZSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctan-2-yl]triacontanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VYEUHMFNZNPCQL-UHTOCBDZSA-N 0.000 description 2
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
101150003085 Pdcl gene Proteins 0.000 description 2
108010081690 Pertussis Toxin Proteins 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000003915 cell function Effects 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
229940125773 compound 10 Drugs 0.000 description 2
229940125797 compound 12 Drugs 0.000 description 2
229940125758 compound 15 Drugs 0.000 description 2
229940126142 compound 16 Drugs 0.000 description 2
229940125782 compound 2 Drugs 0.000 description 2
229940126086 compound 21 Drugs 0.000 description 2
229940126208 compound 22 Drugs 0.000 description 2
229940126214 compound 3 Drugs 0.000 description 2
229940125878 compound 36 Drugs 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
210000001508 eye Anatomy 0.000 description 2
238000005755 formation reaction Methods 0.000 description 2
125000003147 glycosyl group Chemical group 0.000 description 2
CKDDRHZIAZRDBW-UHFFFAOYSA-N henicosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCC(O)=O CKDDRHZIAZRDBW-UHFFFAOYSA-N 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
VXZBFBRLRNDJCS-UHFFFAOYSA-N heptacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O VXZBFBRLRNDJCS-UHFFFAOYSA-N 0.000 description 2
239000002955 immunomodulating agent Substances 0.000 description 2
230000002584 immunomodulator Effects 0.000 description 2
229940121354 immunomodulator Drugs 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
238000011813 knockout mouse model Methods 0.000 description 2
239000010410 layer Substances 0.000 description 2
208000027905 limb weakness Diseases 0.000 description 2
231100000861 limb weakness Toxicity 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
IHEJEKZAKSNRLY-UHFFFAOYSA-N nonacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O IHEJEKZAKSNRLY-UHFFFAOYSA-N 0.000 description 2
UTOPWMOLSKOLTQ-UHFFFAOYSA-N octacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O UTOPWMOLSKOLTQ-UHFFFAOYSA-N 0.000 description 2
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
MWMPEAHGUXCSMY-UHFFFAOYSA-N pentacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O MWMPEAHGUXCSMY-UHFFFAOYSA-N 0.000 description 2
230000009696 proliferative response Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000011734 sodium Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
XEZVDURJDFGERA-UHFFFAOYSA-N tricosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)=O XEZVDURJDFGERA-UHFFFAOYSA-N 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
MPKIDHIOYNMFES-CLTBVUQJSA-N 1-O-(alpha-D-galactopyranosyl)-N-tetracosanyl-2-aminononane-1,3,4-triol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O MPKIDHIOYNMFES-CLTBVUQJSA-N 0.000 description 1
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
RBWNDBNSJFCLBZ-UHFFFAOYSA-N 7-methyl-5,6,7,8-tetrahydro-3h-[1]benzothiolo[2,3-d]pyrimidine-4-thione Chemical compound N1=CNC(=S)C2=C1SC1=C2CCC(C)C1 RBWNDBNSJFCLBZ-UHFFFAOYSA-N 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
235000021357 Behenic acid Nutrition 0.000 description 1
235000011960 Brassica ruvo Nutrition 0.000 description 1
ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
AZPWURBSONBBNI-QNAIHFNASA-N CCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O AZPWURBSONBBNI-QNAIHFNASA-N 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
229940126639 Compound 33 Drugs 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
206010017577 Gait disturbance Diseases 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000021353 Lignoceric acid Nutrition 0.000 description 1
CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
241000872931 Myoporum sandwicense Species 0.000 description 1
OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 1
YEHMKAOSIFGJBH-IWVUWWQKSA-N N-[(2S,3S,4R)-1-(alpha-D-galactopyranosyloxy)-3,4-dihydroxynonan-2-yl]hexacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YEHMKAOSIFGJBH-IWVUWWQKSA-N 0.000 description 1
GJWBIZNVRUQLGM-HKCHYWKBSA-N N-[(2S,3S,4R)-1-[(2S,3R,4R,5R,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxyoctadecan-2-yl]hexacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1N GJWBIZNVRUQLGM-HKCHYWKBSA-N 0.000 description 1
CMWANVMZMAHGFB-CLTBVUQJSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]heptacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O CMWANVMZMAHGFB-CLTBVUQJSA-N 0.000 description 1
VRHXOUGAISIKDW-WVLAUNTOSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]octacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VRHXOUGAISIKDW-WVLAUNTOSA-N 0.000 description 1
WYMMKFZKZKVTPU-NOUVZJLJSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]tricosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O WYMMKFZKZKVTPU-NOUVZJLJSA-N 0.000 description 1
KUCIPEILZSJEFI-QNAIHFNASA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonan-2-yl]henicosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O KUCIPEILZSJEFI-QNAIHFNASA-N 0.000 description 1
SRWCRRGQCGRIQM-NOUVZJLJSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctan-2-yl]henicosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O SRWCRRGQCGRIQM-NOUVZJLJSA-N 0.000 description 1
TXTCFJSBYDYALV-HVPSFVGRSA-N N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctan-2-yl]icosanamide Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O TXTCFJSBYDYALV-HVPSFVGRSA-N 0.000 description 1
208000011644 Neurologic Gait disease Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010047642 Vitiligo Diseases 0.000 description 1
LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
231100000354 acute hepatitis Toxicity 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
238000010640 amide synthesis reaction Methods 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
230000000599 auto-anti-genic effect Effects 0.000 description 1
201000005000 autoimmune gastritis Diseases 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
229940116226 behenic acid Drugs 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000000188 beta-D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000008827 biological function Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000012928 buffer substance Substances 0.000 description 1
RIGUTONFWSZQSU-UHFFFAOYSA-N butylidene(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CCCC)C1=CC=CC=C1 RIGUTONFWSZQSU-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
229940125961 compound 24 Drugs 0.000 description 1
229940125851 compound 27 Drugs 0.000 description 1
229940127204 compound 29 Drugs 0.000 description 1
229940125877 compound 31 Drugs 0.000 description 1
229940125807 compound 37 Drugs 0.000 description 1
239000010779 crude oil Substances 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
KFEVDPWXEVUUMW-UHFFFAOYSA-N docosanoic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 KFEVDPWXEVUUMW-UHFFFAOYSA-N 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
ZRSDQBKGDNPFLT-UHFFFAOYSA-N ethanol;oxolane Chemical compound CCO.C1CCOC1 ZRSDQBKGDNPFLT-UHFFFAOYSA-N 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
NNQYFBSGBOKZKP-UHFFFAOYSA-N ethylidene(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC)C1=CC=CC=C1 NNQYFBSGBOKZKP-UHFFFAOYSA-N 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
210000001145 finger joint Anatomy 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
210000004247 hand Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
UKJFVOWPUXSBOM-UHFFFAOYSA-N hexane;oxolane Chemical compound C1CCOC1.CCCCCC UKJFVOWPUXSBOM-UHFFFAOYSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000005934 immune activation Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000008975 immunomodulatory function Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000003328 mesylation reaction Methods 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
WZUGQQATYIOKAP-DVUMYHMQSA-N n-[(2s)-1-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadecan-2-yl]tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O WZUGQQATYIOKAP-DVUMYHMQSA-N 0.000 description 1
BYYWIHWYIOOORW-ZORUMLJWSA-N n-[(2s,3s,4r)-3,4-dihydroxy-1-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexan-2-yl]hexacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BYYWIHWYIOOORW-ZORUMLJWSA-N 0.000 description 1
HOSXVUOUWZHIIJ-HBGSFDFLSA-N n-[(2s,3s,4r)-3,4-dihydroxy-1-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonan-2-yl]docosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O HOSXVUOUWZHIIJ-HBGSFDFLSA-N 0.000 description 1
YAUMFZQYJPJREV-LQPUHCPASA-N n-[(2s,3s,4r)-3,4-dihydroxy-1-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonan-2-yl]heptacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YAUMFZQYJPJREV-LQPUHCPASA-N 0.000 description 1
ZVSGMEHLTYLXIA-NOUVZJLJSA-N n-[(2s,3s,4r)-3,4-dihydroxy-1-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonan-2-yl]icosanamide Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZVSGMEHLTYLXIA-NOUVZJLJSA-N 0.000 description 1
VFEXAJUPUSLNRS-RQWCFLMLSA-N n-[(2s,3s,4r)-3,4-dihydroxy-1-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonan-2-yl]octacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VFEXAJUPUSLNRS-RQWCFLMLSA-N 0.000 description 1
GJIILCQVXXLNJF-WVLAUNTOSA-N n-[(2s,3s,4r)-3,4-dihydroxy-1-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonan-2-yl]pentacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O GJIILCQVXXLNJF-WVLAUNTOSA-N 0.000 description 1
ZCVDUGOOIVPIKZ-ZORUMLJWSA-N n-[(2s,3s,4r)-3,4-dihydroxy-1-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonan-2-yl]tricosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZCVDUGOOIVPIKZ-ZORUMLJWSA-N 0.000 description 1
DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 1
IIMNMDYAGLBIOT-UHFFFAOYSA-N octadecan-4-ol Chemical compound CCCCCCCCCCCCCCC(O)CCC IIMNMDYAGLBIOT-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
244000052769 pathogen Species 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
150000003109 potassium Chemical class 0.000 description 1
CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical class [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000013558 reference substance Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000012552 review Methods 0.000 description 1
102220079670 rs759826252 Human genes 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000001119 stannous chloride Substances 0.000 description 1
235000011150 stannous chloride Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
QZZGJDVWLFXDLK-UHFFFAOYSA-N tetracosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(O)=O QZZGJDVWLFXDLK-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000007070 tosylation reaction Methods 0.000 description 1
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
DDMOZUBZYFKJDS-UHFFFAOYSA-N triphenyl(propylidene)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CCC)C1=CC=CC=C1 DDMOZUBZYFKJDS-UHFFFAOYSA-N 0.000 description 1
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
208000006961 tropical spastic paraparesis Diseases 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Crystallography & Structural Chemistry (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO20040653A 2001-08-16 2004-02-13 Nytt glykolipid og medisin for autoimmunsykdom inneholdende det samme som aktiv ingrediens. NO326398B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001247055		2001-08-16
PCT/JP2002/008280 WO2003016326A1 (fr)	2001-08-16	2002-08-14	Glycolipide et agent therapeutique pour maladies auto-immunes le contenant en tant qu'ingredient actif

Publications (2)

Publication Number	Publication Date
NO20040653L NO20040653L (no)	2004-05-07
NO326398B1 true NO326398B1 (no)	2008-11-24

Family

ID=19076468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20040653A NO326398B1 (no)	2001-08-16	2004-02-13	Nytt glykolipid og medisin for autoimmunsykdom inneholdende det samme som aktiv ingrediens.

Country Status (15)

Country	Link
US (1)	US8367623B2 (fr)
EP (1)	EP1437358B1 (fr)
JP (1)	JP4064346B2 (fr)
KR (1)	KR100880063B1 (fr)
CN (1)	CN100439383C (fr)
AT (1)	ATE342910T1 (fr)
AU (1)	AU2002327097B2 (fr)
BR (1)	BR0211968A (fr)
CA (1)	CA2459482C (fr)
DE (1)	DE60215530T2 (fr)
DK (1)	DK1437358T3 (fr)
ES (1)	ES2274080T3 (fr)
HU (1)	HU229345B1 (fr)
NO (1)	NO326398B1 (fr)
WO (1)	WO2003016326A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9809654B2 (en)	2002-09-27	2017-11-07	Vaccinex, Inc.	Targeted CD1d molecules
US7732583B2 (en) *	2003-02-14	2010-06-08	Japan As Represented By President Of National Center Of Neurology And Psychiatry	Glycolipids and synthetic method thereof as well as their synthetic intermediates, and synthetic intermediates, and synthetic method thereof
EP1784196B1 (fr) *	2004-08-27	2016-12-21	Albert Einstein College Of Medicine Of Yeshiva University	Derives de ceramides utilises comme modulateur d'immunite et d'auto-immunite
TWI382843B (zh)	2004-10-07	2013-01-21	Argos Therapeutics Inc	成熟樹突細胞組合物及培養彼等之方法
US8513008B2 (en)	2004-10-07	2013-08-20	Argos Therapeutics, Inc.	Mature dendritic cell compositions and methods for culturing same
US7534434B2 (en) *	2004-12-28	2009-05-19	The Rockefeller University	Glycolipids and analogues thereof as antigens for NK T cells
US7923013B2 (en)	2004-12-28	2011-04-12	The Rockefeller University	Glycolipids and analogues thereof as antigens for NKT cells
JP4909264B2 (ja) *	2005-04-01	2012-04-04	独立行政法人理化学研究所	経鼻ワクチン
BRPI0612732A2 (pt) *	2005-07-01	2011-08-16	Japan As Represented By The President Of Nat Ct Of Neurology And Psychiatry	derivado de glicolipìdeo e uso do mesmo
EP1952814A1 (fr) *	2005-10-28	2008-08-06	Japan as represented by President of National Center of Neurology and Psychiatry	Agent therapeutique comprenant un derive de glycolipide capable d inhiber la fonction de cellules nkt
US8163705B2 (en)	2006-02-28	2012-04-24	Riken	Glycolipid and use thereof
CA2655947C (fr)	2006-06-30	2016-08-02	The Scripps Research Institute	Compositions comprenant des composes agonistes des cellules nkt et procedes d'utilisation
KR100868959B1 (ko) *	2006-12-30	2008-11-17	재단법인서울대학교산학협력재단	알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물
WO2008103392A2 (fr)	2007-02-21	2008-08-28	Vaccinex, Inc.	Modulation d'activité de cellule nkt avec des molécules cdid chargées en antigène
CA2702344C (fr) *	2007-10-12	2016-09-27	Luigi Panza	Analogues de glycolipides en tant qu'immunoadjuvants
EP2385980B1 (fr) *	2009-01-08	2018-04-18	Albert Einstein College of Medicine, Inc.	Vaccins bactériens avec des glycolipides du type céramide associés à la paroi cellulaire et leurs utilisations
US9371352B2 (en)	2013-02-08	2016-06-21	Vaccinex, Inc.	Modified glycolipids and methods of making and using the same
JP6202339B2 (ja)	2013-12-19	2017-09-27	国立研究開発法人国立精神・神経医療研究センター	ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤
KR102376846B1 (ko)	2014-02-26	2022-03-21	국립대학법인 홋가이도 다이가쿠	수지상 세포를 함유하는 의약 및 그 제조 방법
CN114096260A (zh)	2019-07-12	2022-02-25	国立大学法人九州大学	心肌收缩改善治疗法和心肌细胞死亡抑制法的开发
AU2020475870A1 (en) *	2020-11-06	2023-06-15	National Center Of Neurology And Psychiatry	Therapeutic agent for progressive disease caused by increase in eomes-positive cd4-positive t cells
EP4301374A4 (fr)	2021-03-01	2025-09-10	Deciduous Therapeutics Inc	Composés pour activer des lymphocytes t tueurs naturels invariants et méthodes d'utilisation dans l'élimination de cellules sénescentes inflammatoires

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5827828A (ja) *	1981-08-11	1983-02-18	Mitsubishi Electric Corp	燃料噴射装置
DK84691D0 (da) *	1991-05-07	1991-05-07	Karsten Buschard	Visse glycolipider og specifikke catchere for disse til anvendelse ved profylaxe eller terapi af diabetes, og/eller dermed forbundne komplikationer samt anvendelse af saadanne glycolipider til detektion af oe-celle-antistoffer (ica) i et individ og anvendelse af saadanne catchere til detektion af langerhans-oe-celler i pancreas-praeparater
US5936076A (en) *	1991-08-29	1999-08-10	Kirin Beer Kabushiki Kaisha	αgalactosylceramide derivatives
JPH0559081A (ja)	1991-08-29	1993-03-09	Kirin Brewery Co Ltd	新規スフインゴ糖脂質、その製造法および使用
GB9207182D0 (en) *	1992-04-01	1992-05-13	Enzymatix Ltd	Glycolipids and their preparation
TW261533B (fr) *	1992-07-16	1995-11-01	Kirin Brewery
CA2142153A1 (fr) *	1994-03-04	1995-09-05	Jacques Banville	Derives .beta.-glycolipidiques sulfates, inhibiteurs de l'adherence cellulaire
DE69504134T2 (de) *	1994-05-31	1999-02-04	Seikagaku Kogyo K.K., Tokio/Tokyo	Glycolipidanalogen als Glukosidaseinhibitoren
DE19602108A1 (de)	1996-01-22	1997-07-24	Beiersdorf Ag	Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Substanzen
JP4451933B2 (ja) *	1996-12-27	2010-04-14	住友化学株式会社	遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法
ES2235324T3 (es)	1997-04-10	2005-07-01	Kirin Beer Kabushiki Kaisha	Empleo de a-glicosilceramidas para la obtencion de un agente terapeutico para enfermedades autoinmunes.
US6589940B1 (en) *	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
TW575420B (en) *	1997-09-22	2004-02-11	Kirin Brewery	Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US7273711B1 (en) *	1998-12-02	2007-09-25	The Regents Of The University Of California	Diagnosis of human glycosylation disorders
JP2002284692A (ja) *	2001-03-26	2002-10-03	Kirin Brewery Co Ltd	α−グリコシルセラミドによる移植片対宿主病（ＧＶＨＤ）の抑制

2002
- 2002-08-14 EP EP02760637A patent/EP1437358B1/fr not_active Expired - Lifetime
- 2002-08-14 KR KR1020047002291A patent/KR100880063B1/ko not_active Expired - Lifetime
- 2002-08-14 WO PCT/JP2002/008280 patent/WO2003016326A1/fr not_active Ceased
- 2002-08-14 AT AT02760637T patent/ATE342910T1/de not_active IP Right Cessation
- 2002-08-14 AU AU2002327097A patent/AU2002327097B2/en not_active Expired
- 2002-08-14 US US10/486,948 patent/US8367623B2/en not_active Expired - Fee Related
- 2002-08-14 CN CNB028203615A patent/CN100439383C/zh not_active Expired - Lifetime
- 2002-08-14 JP JP2003521248A patent/JP4064346B2/ja not_active Expired - Lifetime
- 2002-08-14 DE DE60215530T patent/DE60215530T2/de not_active Expired - Lifetime
- 2002-08-14 BR BR0211968-4A patent/BR0211968A/pt not_active IP Right Cessation
- 2002-08-14 DK DK02760637T patent/DK1437358T3/da active
- 2002-08-14 HU HU0500127A patent/HU229345B1/hu unknown
- 2002-08-14 ES ES02760637T patent/ES2274080T3/es not_active Expired - Lifetime
- 2002-08-14 CA CA2459482A patent/CA2459482C/fr not_active Expired - Lifetime
2004
- 2004-02-13 NO NO20040653A patent/NO326398B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
US8367623B2 (en)	2013-02-05
DK1437358T3 (da)	2007-02-05
US20060148723A1 (en)	2006-07-06
HU229345B1 (en)	2013-11-28
EP1437358A4 (fr)	2004-11-24
JP4064346B2 (ja)	2008-03-19
WO2003016326A1 (fr)	2003-02-27
DE60215530T2 (de)	2007-05-31
EP1437358A1 (fr)	2004-07-14
NO20040653L (no)	2004-05-07
JPWO2003016326A1 (ja)	2004-12-02
EP1437358B1 (fr)	2006-10-18
CA2459482C (fr)	2010-09-28
AU2002327097B2 (en)	2007-05-24
BR0211968A (pt)	2004-09-28
KR20040039287A (ko)	2004-05-10
HUP0500127A2 (en)	2006-09-28
ATE342910T1 (de)	2006-11-15
CA2459482A1 (fr)	2003-02-27
HUP0500127A3 (en)	2009-12-28
DE60215530D1 (de)	2006-11-30
ES2274080T3 (es)	2007-05-16
CN1568328A (zh)	2005-01-19
KR100880063B1 (ko)	2009-01-22
CN100439383C (zh)	2008-12-03

Publication	Publication Date	Title
NO326398B1 (no)	2008-11-24	Nytt glykolipid og medisin for autoimmunsykdom inneholdende det samme som aktiv ingrediens.
CA2140013C (fr)	2002-08-27	Compositions pharmaceutiques contenant des galactosylceramides
CA2116442C (fr)	2000-09-05	Nouveaux glucosphingolipides et leur utilisation
JP3865411B2 (ja)	2007-01-10	抗−エンドトキシン化合物
JP3717512B2 (ja)	2005-11-16	新規スフィンゴ糖脂質およびその使用
DE69416306T2 (de)	1999-06-17	Sphingoglycolipid und verwendung davon
JPWO1994002168A1 (ja)	1994-08-04	新規医薬組成物
JPWO1994009020A1 (ja)	1994-11-02	新規スフィンゴ糖脂質およびその使用
WO2009119692A1 (fr)	2009-10-01	Nouveau glycolipide et son utilisation
TW479061B (en)	2002-03-11	Sialic acid derivatives
KR100473325B1 (ko)	2005-07-28	항바이러스활성을가진신규화합물
CN114805454A (zh)	2022-07-29	α-半乳糖神经酰胺类化合物及其制备方法和用途
HUT74449A (en)	1996-12-30	Medicinal compositions contg. alpha-galactosyl-ceramides
HK1009967B (en)	2000-06-23	Novel sphingoglycolipid and use thereof
HK1009937B (en)	2001-08-17	Novel medicinal composition

Legal Events

Date	Code	Title	Description
2022-09-12	MK1K	Patent expired